Background
Methods
Study design and sampling
Data collection
Study outcomes
Statistical analysis
Results
Baseline characteristics of patients with relapse and no relapse
Relapse
| ||||||
---|---|---|---|---|---|---|
Yes (N = 540) | No (N = 484) | |||||
M (SD)1
| M (SD) | p-value | Crude HR | 95% CI | p-value | |
Socio-demographic characteristics | ||||||
Age | 40.3 (10.1) | 42. 0 (11.6) | p = 0.013 | 0.99 | (0.98;0.99) | p = 0.004 |
Gender (Male), N (%)2
| 62.1 | 61.2 | p = 0.773 | 0.97 | (0.82;1.16) | p = 0.762 |
Living alone, N (%) | 33.5 | 34.5 | p = 0.740 | 0.97 | (0.81;1.16) | p = 0.754 |
Unemployed, N (%) | 56.9 | 35.7 | P = 0.240 | 0.79 | (0.53;1.15) | p = 0.237 |
Severity of symptoms: PANSS3
| ||||||
Positive PANSS score | 12.7 (5.7) | 11.7 (5.1) | p = 0.003 | 1.03 | (1.01;1.04) | p = 0.001 |
Negative PANSS score | 16.1 (7.3) | 14.6 (7.5) | p = 0.002 | 1.02 | (1.01;1.03) | p = 0.001 |
General Psychopathology PANSS score | 29.7 (10.2) | 27.7 (10.1) | P = 0.001 | 1.02 | (1.01;1.02) | p < 0.001 |
Functioning | ||||||
GAF4
| 48.5 (15.6) | 55.0 (15.9) | p < 0.001 | 0.98 | (0.98;0.99) | p < 0.001 |
Side Effects | ||||||
BAS5
| 1.3 (3.0) | 1.1 (2.7) | p = 0.192 | 1.02 | (0.99;1.04) | p = 0.147 |
AIMS6
| 3.0 (6.9) | 2.5 (5.6) | p = 0.228 | 1.01 | (0.99;1.02) | p = 0.328 |
SAS7
| 3.5 (8.2) | 3.5 (7.7) | p = 0.963 | 1.00 | (0.99;1.011) | p = 0.990 |
Medication | ||||||
Second-generation antipsychotics (Yes), N (%) | 45.6 | 38.9 | p = 0.034 | 1.26 | (1.06;1.49) | p = 0.009 |
Attitude towards medication: ROMI8
| ||||||
ROMI compliance score | 10.8 (3.5) | 11.1 (3.1) | p = 0.223 | 0.97 | (0.95;0.99) | p = 0.035 |
Quality of life | ||||||
SF36 - Physical Composite Score * | 47.2 (9.8) | 49.1 (8.7) | p = 0.001 | 0.83 | (0.76;0.91) | p < 0.001 |
SF36 - Mental Composite Score ** | 40.3 (11.8) | 43.7 (11.0) | p < 0.001 | 0.84 | (0.78;0.91) | p < 0.001 |
QoLI - OLS score***
| 4.7 (0.9) | 4.8 (0.8) | p = 0.006 | 0.86 | (0.78;0.95) | p = 0.003 |
Predictors of relapse in the Cox’s proportional hazard models
Discussion
SF-36 Model | QoLI Model | |||||
---|---|---|---|---|---|---|
HR | 95% IC | p-value | HR | 95% IC | p-value | |
Quality of life | ||||||
SF36 - Physical Composite Score * | 0.82 | (0.74;0.91) | p < 0.001 | - | - | - |
SF36 - Mental Composite Score ** | 0.88 | (0.81;0.96) | p = 0.002 | - | - | - |
QoLI - OLS score*** | - | - | - | 0.91 | (0.81;1.01) | p = 0.083 |
Socio-demographic characteristics | ||||||
Age | 0.98 | (0.98;0.99) | p = 0.001 | 0.98 | (0.98;0.99) | p < 0.001 |
Gender (Male) | 1.06 | (0.88;1.30) | p = 0.532 | 1.12 | (0.93;1.34) | p = 0.249 |
Severity of symptoms: PANSS1
| ||||||
Positive PANSS score | 0.99 | (0.97;1.02) | p = 0.514 | 0.99 | (0.97;1.02) | p = 0.560 |
Negative PANSS score | 1.01 | (0.99;1.03) | p = 0.248 | 1.00 | (0.98;1.02) | p = 0.969 |
General Psychopathology PANSS score | 0.99 | (0.97;1.01) | p = 0.419 | 1.00 | (0.98;1.02) | p = 0.937 |
Functioning | ||||||
GAF2
| 0.98 | (0.97;0.99) | p < 0.001 | 0.98 | (0.97;0.99) | p < 0.001 |
Side Effects | ||||||
BAS3
| 0.99 | (0.95;1.02) | p = 0.497 | 1.00 | (0.97;1.03) | p = 0.844 |
Medication | ||||||
Second-generation antipsychotics (Yes) | 1.07 | (0.88;1.29) | p = 0.508 | 1.13 | (0.94;1.36) | p = 0.195 |
Attitude towards medication: ROMI4
| ||||||
ROMI compliance score | 0.97 | (0.94;0.99) | p = 0.041 | 0.97 | (0.95;1.00) | p = 0.063 |